Bioprofarma Bagó Announces In-Licensing Exclusive Partnership with Polaris Pharmaceuticals to introduce ADI-PEG20

Buenos Aires, Argentina – Bioprofarma Bagó (a fully owned subsidiary of GRUPO EMPRESARIAL BAGO), today announced an exclusive licensing agreement with Polaris, a renowned American pharmaceutical company, to introduce ADI-PEG20 (ADZODI®), a novel treatment for Malignant Pleural Mesothelioma (MPM) to the LATAM. This partnership is set to improve the treatment landscape by delivering innovative therapeutic...

New release LIPECELTE® trabectedin

Introducing LIPECELTE® Trabectedin: A New Addition to Our Oncology Line At Bioprofarma Bagó, we reaffirm our dedication to patient care with the launch of LIPECELTE® trabectedin, approved by ANMAT for the treatment of: – Advanced soft tissue sarcoma (STS) in adult patients who have failed anthracycline and ifosfamide treatment or are not candidates for these therapies.– Platinum-sensitive recurrent ovarian cancer,...

FUCDIM Uro-Oncology Conference

Bioprofarma Bagó was present on October 24th and 25th at the Uro-Oncology Conference: Controversies and New Developments 2024, organized by the FUCDIM Urology Center in the city of Córdoba.The conference discussions focused on:- High-risk and locally advanced prostate cancer- Non-muscle-invasive bladder cancer (NMIBC)Our representative, Mariano Nalbandian, led the promotion and communication of our CarciVac® product,...

New Product Launch NILTARA®nilotinib

Bioprofarma Bagó is pleased to present the launch of the product NILTARA® nilotinib, for its Hematology Line. This new product has been approved by ANMAT for the treatment of: Adult and pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML), recently diagnosed, in chronic phase; Adult patients with Philadelphia chromosome-positive CML in chronic phase and accelerated phase, with resistance...

LACE Congress 2024

The Argentine League Against Epilepsy 2024 Congress took place on September 26th and 27th at the Palais Rouge. For the second consecutive year, Bioprofarma Bagó was present in the trade hall with a booth and actively promoted our product for refractory epilepsy: KALISMA® sultiame. Our sales representatives, Dario Campos, Eduardo Montero, and Gustavo Safe, engaged with the...

61st Argentine Congress of Urology

The 61st Argentine Congress of Urology, organized by the Argentine Society of Urology, was held on September 4th, 5th, and 6th at the Sheraton Hotel in Buenos Aires. The Congress featured presentations by international and national speakers addressing various urological pathologies, as well as scientific case presentations. Our team had a booth in the trade show hall,...

Launch of UroControl®

On Tuesday, September 3rd, we launched a new product, UroControl®, an innovative test for the early detection of relapses in non-muscle-invasive bladder cancer. Bioprofarma Bagó signed a promotional agreement with Argenomics to strengthen its Urology portfolio. UroControl® is a liquid biopsy that, using advanced molecular biology techniques, detects key mutations in the TERT, FGFR3, and KRAS...

New Product Lunch IMPILO®bexarotene

Bioprofarma Bagó is pleased to introduce IMPILO® bexarotene, for its Hematology Line, replacing the historical TARGRETIN® bexarotene. Based on its experience to maintain the same quality standards that characterize the company, IMPILO® bexarotene was developed locally, which will benefit supply, helping patients access to continue their treatments. IMPILO® bexarotene is approved by ANMAT for...

XXVI Argentine and International Congress of Clinical Oncology organized by the AAOC

November 8-10, the XXVI Argentine and International Congress of Clinical Oncology 2023 was held at the La Rural property, in the City of Buenos Aires. Under the tagline “Cancer at the center of the community and science”, the congress featured the participation and presentations of national and international professionals, offering simultaneous sessions in the nine available...